ArticleCancer medicine2025
ER Stress Induced by Artemisinin and Its Derivatives Determines the Susceptibility to Their Synergistic Apoptotic Killing With TRAIL.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Tumoricidal efficacy of DZ-1 dye conjugated to dihydroartemisinin in patient-derived colorectal liver metastasis tumoroids.Molecular therapy. Oncology · 2026Article
- Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges.Neurology international · 2026Review
- The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment.International journal of molecular sciences · 2026Review
- DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroids.Frontiers in pharmacology · 2026Article
- ER Stress Induced by Artemisinin and Its Derivatives Determines the Susceptibility to Their Synergistic Apoptotic Killing With TRAIL.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimArtemisinins are a class of antimalarial drugs that are lately being researched for their antitumor activity. We previously reported that artesunate, an artemisinin derivative, can induce ferroptosis and enhance TRAIL (Tumor necrosis factor-Related Apoptosis-Inducing Ligand)-induced apoptosis. Here we investigated the role of endoplasmic reticulum (ER) stress induced by artemisinin and its derivatives, especially in the enhancement of TRAIL-induced apoptosis, which can be exploited for repurposing the use of artemisinins in cancer therapy.
methodsWe show in this study a comparative profile of the ER stress induced by different derivatives of this drug, namely artemisinin, artesunate, arteether, artemether, and dihydroartemisinin, all of which are available readily and approved for treating human patients. These five derivatives were used to treat human colon carcinoma HCT116 cells and pancreatic adenocarcinoma BxPC3 cells over a range of doses.
resultsOur data show a highly significant positive correlation between ER stress caused by these drugs and their corresponding apoptotic susceptibilities upon treatment with TRAIL.
conclusionWe concluded that dihydroartemisinin is the most effective contender among all the derivatives tested to enhance TRAIL-induced apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.